(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

European and Asian stocks markets closed out the week broadly higher Friday following Wall Street's latest record highs ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

U.S. stocks appear poised for a positive opening on Friday, as strong earnings from major companies throughout the week have ...

As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

Many people think that Warren Buffet is a good lead indicator for financial markets, and Berkshire Hathaway has been offloading US banks in recent months. Many people may ask why sell stocks when they ...

Corona Remedies acquires cardiology and women's healthcare brands from Bayer, entering new segments ahead of IPO.